Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AeroVeil
- Development stage
- Preclinical
- Lead developer
- Luna Labs
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
AeroVeil is a sprayable hydrogel developed by Luna Labs, currently in preclinical development. It is designed to reduce the incidence of abdominal adhesions and enhance wound healing following surgical procedures, with a specific focus on post-cesarean uterine recovery. The hydrogel is applied as a spray that forms a protective barrier over the surgical site, preventing tissues from sticking together during the healing process and minimizing post-operative scar formation. By providing a physical barrier and a supportive matrix, AeroVeil aims to improve surgical outcomes and reduce complications associated with adhesion formation.
- Brand names
- AeroVeil
- Other names
- AeroVeil Sprayable Hydrogel
Beyond the preview
Go deeper on AeroVeil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AeroVeil.